Trex Wind-down Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

John Koconis

Chief executive officer

US$692.6k

Total compensation

CEO salary percentage	53.5%
CEO tenure	4yrs
CEO ownership	0.01%
Management average tenure	4yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Koconis's remuneration changed compared to Trex Wind-down's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-US$15m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$693k	US$371k	-US$19m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$995k	US$357k	-US$11m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$1m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$507k	US$289k	-US$15m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$280k	US$79k	-US$4m

Compensation vs Market: John's total compensation ($USD692.59K) is about average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Koconis (52 yo)

4yrs

Tenure

US$692,594

Compensation

Mr. John Koconis, MBA, serves as Chairman and President at Trex Wind-down, Inc. (formerly known as Timber Pharmaceuticals, Inc.) since April 20, 2021. Mr. Koconis serves as Chief Executive Officer at Trex...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Koconis	Chairman	4yrs	US$692.59k	0.013% $ 0.04
Joseph Lucchese	Executive VP	4yrs	US$603.50k	0% $ 0
Alan Mendelsohn	Executive VP & Chief Medical Officer	3.3yrs	US$568.36k	0.0016% $ 0.005

4.0yrs

Average Tenure

55yo

Average Age

Experienced Management: TMBR.Q's management team is considered experienced (4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Koconis	Chairman	4yrs	US$692.59k	0.013% $ 0.04
Edward Sitar	Lead Independent Director	4yrs	US$131.62k	0.16% $ 0.5
Lubor Gaal	Independent Director	3.8yrs	US$107.37k	0.11% $ 0.3
David Cohen	Independent Director	3.8yrs	US$113.63k	0.11% $ 0.3
Gianluca Pirozzi	Independent Director	4yrs	US$108.87k	0.11% $ 0.3

4.0yrs

Average Tenure

54yo

Average Age

Experienced Board: TMBR.Q's board of directors are considered experienced (4 years average tenure).

Trex Wind-down Management

Management criteria checks 4/4

Key information

Recent management updates

High number of new and inexperienced directors

High number of new and inexperienced directors

Timber Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2022

High number of new and inexperienced directors

Timber Pharmaceuticals, Inc. Announces Management Changes

Recent updates

Timber Pharmaceuticals, Inc. Presents Preliminary Results from the ASCEND Trial in A Late-Breaking Session At the 2024 American Academy of Dermatology (AAD) Annual Meeting

Timber Pharmaceuticals Receives Written Notice from the Staff of NYSE Regulation

Timber Pharmaceuticals, Inc.(NYSEAM:TMBR) dropped from S&P TMI Index

Timber Pharmaceuticals, Inc. Filed for Bankruptcy

Timber Pharmaceuticals, Inc. announced delayed 10-Q filing

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

LEO Pharma A/S entered into a definitive agreement to acquire Timber Pharmaceuticals, Inc. (NYSEAM:TMBR) for $8.1 million.

Timber Pharmaceuticals Discloses Communication from NYSE American

Timber Pharmaceuticals Regains Compliance With NYSE American Continued Listing Standards

Third quarter 2022 earnings released: US$1.52 loss per share (vs US$4.15 loss in 3Q 2021)

High number of new and inexperienced directors

Timber Pharmaceuticals, Inc. announced that it has received funding

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.082 loss in 2Q 2021)

Timber Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Timber Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Timber Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 3 Ascend Clinical Trial Evaluating Tmb-001 in Congenital Ichthyosis

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis

First quarter 2022 earnings released: US$0.048 loss per share (vs US$0.054 loss in 1Q 2021)

High number of new and inexperienced directors

Timber Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2022

Full year 2021 earnings released: US$0.27 loss per share (vs US$0.97 loss in FY 2020)

Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis

High number of new and inexperienced directors

Timber Pharmaceuticals, Inc. Provides Update of Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2B Control Study Evaluating TMB-001 in Congenital Ichthyosis

First quarter 2021 earnings released: US$0.054 loss per share (vs US$0.30 loss in 1Q 2020)

Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001

Executive Chairman of the Board Michael Derby has left the company

Full year 2020 earnings released: US$0.97 loss per share

Timber Pharmaceuticals Announces 50% Enrollment in Phase 2B Control Study in Congenital Ichthyosis

New 90-day high: US$3.44

New 90-day high: US$1.47

Timber Pharmaceuticals, Inc. Announces Management Changes

Timber Pharmaceuticals, Inc. Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis

New 90-day low: US$0.89

Timber Pharmaceuticals, Inc. announced delayed 10-Q filing

Timber Pharmaceuticals LLC completed the acquisition of BioPharmX Corporation (AMEX:BPMX) in a reverse merger transaction.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age